Rigel Reports First Quarter 2026 Financial Results

May 6, 2026 - 01:50

Rigel Pharmaceuticals reported its financial results for the first quarter of 2026, posting total revenues of $58.8 million. The figure includes net product sales of $54.9 million and contract revenues from collaborations totaling $3.9 million.

The company's performance in the opening months of the year reflects ongoing demand for its commercial-stage products. Net product sales, which form the bulk of the revenue stream, showed stability compared to recent quarters. The collaboration revenue, while a smaller portion, continues to contribute to the overall top line through existing partnership agreements.

Rigel did not provide specific net income or earnings per share figures in the initial release, but the revenue numbers offer a snapshot of the company's commercial momentum. The pharmaceutical firm has been focused on expanding its portfolio of treatments for hematologic disorders and other conditions.

Management highlighted the quarter's results as a sign of steady execution in both sales and research efforts. The company also reiterated its commitment to advancing its pipeline, though no new clinical milestones were announced alongside the financial update. Investors and analysts will likely look for more details on cost management and future guidance in the full earnings report.

Rigel's stock saw modest movement in after-hours trading following the announcement, as the market digested the revenue data against expectations. The company is scheduled to hold a conference call later this week to discuss the results in greater depth.